Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator seeking to enhance the bioavailability of multiple active pharmaceutical ingredients using its patented DehydraTECH(TM) drug del… Read More
Calgary, Alberta--(Newsfile Corp. - October 19, 2023) - Timeless Capital Corp. (TSXV: TLC.P) ("Timeless" or the "Corporation"), a capital pool company as defined under TSX Venture Exchange (… Read More
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has granted a new global, exclusive license to SulfoSyn Limited; the license is for the exclusive glo… Read More
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has been granted two new patents by the Canadian Intellectual Property Office… Read More
Phase 1 clinical data to be released in conjunction with Investor DayThis document replaces and updates the previous version with the current OTCQB ticker for Skye Bioscience, Inc.San Diego… Read More
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported results from its human oral nicotine study NIC-H22-1, comparing Lexaria’s Dehy… Read More
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its intention to launch new human and animal studies to examine DehydraTECH(TM)-proce… Read More
Horticulture Bioplastic Market is worth USD 4.12 Billion in 2022 and is estimated to grow at a CAGR of 12.2% in the forecasted period. The forecasted revenue hints at around 9.43 b… Read More
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently celebrated the receipt of U.S. patent #11,700,875, titled “Compositions and Methods For… Read More
DelveInsight’s, “Pancreatic Cancer Pipeline Insight 2023” report provides comprehensive insights about 290+ companies and 300+ pipeline drugs in the Pancreatic Cancer pipe… Read More
The ADA reports that 37.3 million Americans had diabetes in 2019, and the number has been growing by an average 1.4 million each year
95% of Americans with diabetes are diagnosed wi… Read More
[Research Report] The veterinary diagnostics market size is expected to grow from US$ 4,045.50 million in 2022 to US$ 7,270.43 million by 2030; it is estimated to register a CAGR o… Read More
Here are Wednesday’s biggest calls on Wall Street: HSBC upgrades Johnson Controls to buy from hold HSBC said it sees an attractive entry point for the stock. ” Johnson Contro… Read More
Capital marketers, insurance and wealth management experts, investment bankers, individual investors, and research analysts, are invited to attend the Dawson James Small Cap Growth Confere… Read More
Persistence Market Research delivers key insights and views on the global fresh yeast market in its upcoming outlook titled, ‘Fresh Yeast Market: Global Industry Analysis 2013-201… Read More
[Research Report] The swine diagnostics market was valued at US$ 194.15 million in 2022 and is projected to reach a value of US$ 385.39 million by 2030; it is anticipated to record a CA… Read More
Lexaria’s new patent includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in… Read More
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Pulmonary Hypertension pipeline constitutes 80+ key companies continuously working towards developing 8… Read More
The bioavailability enhancement technologies and services market is expected to reach $10 billion by 2035, growing at a CAGR of approximately 11%
Drug developers are shifting focus… Read More
Lexaria just released its mid-year update, highlighting its key milestones so far and its objectives going forward, summarized in a recent Zacks update
Of note was the company&rsquo… Read More
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently completed its animal study HOR-A22-1, which showed that the company’s patented DehydraT… Read More
Diabetes – Blood glucose levels reduced by 19.9% with patented DehydraTECH(TM) processed CBD
Epilepsy – Lower dosages of DehydraTECH-CBD were needed to achieve the same… Read More
Madison, Wisconsin--(Newsfile Corp. - August 18, 2023) - Building on Wisconsin's statewide position of strength in personalized medicine, biohealth technology, precision manufacturing and au… Read More
Lexaria just announced additional findings from its HYPER-H21-4 human clinical study, highlighting significant reductions in several pro-inflammatory biomarkers associated with cardiovascu… Read More
Lexaria just announced the completion of batch manufacturing of its patented DehydraTECH(TM)-processed CBD and placebo materials for its FDA Phase 1b HYPER-H23-1 human clinical study… Read More
Hemoglobinopathy Market 2023
The health systems and data are moving to cloud. Healthcare vertical has several sprawling networks, inclusive of hospitals systems and universities, which… Read More